Cell and gene therapies (CGTs) or advanced therapy medicinal products (ATMPs) in the EU offer new hope in treating previously untreatable illnesses, including cancers, chronic conditions, and rare diseases. This has led to a surge in innovative CGTs entering clinical trials, potentially marking a golden age for contract research organizations (CROs) as they manage complex logistical demands within the cell therapy supply chain while prioritizing investigator well-being and participant comfort.

Despite growth in the CGT field, limited approved therapies and unique logistical challenges can leave CROs inexperienced. Our white paper, developed in collaboration with IQVIA, explores the crucial partnership between CROs and specialty logistics in CGT clinical trials, unveiling strategies and insights for success in this rapidly evolving field of cell therapy logistics.

Key takeaways:

• An understanding of the unique logistical needs in CGT trials and the demand for tailored infrastructure solutions
• The pain points and logistical challenges of CGT trials
• How innovative strategies are emerging to overcome logistical hurdles in CGT trials
• World Courier pivotal role in enabling and supporting CROs engaged in CGT trials
• Looking ahead, what is the future for CGTs?